Principal Financial Group
PRTK

Principal Financial Group’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Principal Financial Group’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-26,912
Closed -$52K – 2595
2022
Q2 		$52K Sell
26,912
-6,389
-19% -$13.9K ﹤0.01% 2461
2022
Q1 		$99K Sell
33,301
-16,915
-34% -$63.6K ﹤0.01% 2427
2021
Q4 		$225K Sell
50,216
-5,442
-10% -$25.8K ﹤0.01% 2328
2021
Q3 		$271K Sell
55,658
-44,525
-44% -$245K ﹤0.01% 2341
2021
Q2 		$683K Buy
+100,183
New +$810K ﹤0.01% 2137
2021
Q1 		– Sell
-10,509
Closed -$66K – 2511
2020
Q4 		$66K Buy
+10,509
New +$61.8K ﹤0.01% 2381

Other funds holding PRTK

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
1CM
1492 Capital Management Milwaukee, Wisconsin $263M AUM 61.9% 1-Year Est. Return

Principal Financial Group's PRTK Position: Q3 2022 in Review

Principal Financial Group sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2022, closing a stake of 26,912 shares — an estimated $52K sold.

Principal Financial Group first reported a position in PRTK in Q4 2020 and held it in 6 quarters. The position peaked at $683K in Q2 2021. 72 funds tracked by Wall St. Rank hold PRTK as of Q3 2022.

  • Principal Financial Group reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2022 after selling out during the quarter.
  • Principal Financial Group sold 26,912 Paratek Pharmaceuticals, Inc. shares in Q3 2022, an estimated $52K.
  • Principal Financial Group first reported a position in Paratek Pharmaceuticals, Inc. in Q4 2020 and held it in 6 quarters.
  • Principal Financial Group's Paratek Pharmaceuticals, Inc. position peaked at $683K in Q2 2021.
  • 72 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2022.

Based on Principal Financial Group's 13F filing for Q3 2022, filed 9 Nov 2022.